Clinical Trial Update: To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating DNA damage repair–targeting strategies with Olaparib versus Olaparib monotherapy in metastatic triple-negative breast cancer; results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Triple Negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-03-22